Over 70-85% of men with advanced prostate cancer (PCa) develop bone metastases that are characterized by severe bone pain. Bone fractures and refractory bone pain are associated with metastatic skeletal pathologies such as osteolytic lesions and abnormal osteoblastic activity. These processes give rise to decreased quality of life and predict higher mortality rates. Studies examining bone pain in prostate cancer are limited and those doing so in immunocompetent models are rare. In this study we sought to examine the contribution of the immune system to bone pain and have created a novel model to study underlying mechanisms.
INTRODUCTION AND OBJECTIVES:
Over 70-85% of men with advanced prostate cancer (PCa) develop bone metastases that are characterized by severe bone pain. Bone fractures and refractory bone pain are associated with metastatic skeletal pathologies such as osteolytic lesions and abnormal osteoblastic activity. These processes give rise to decreased quality of life and predict higher mortality rates. Studies examining bone pain in prostate cancer are limited and those doing so in immunocompetent models are rare. In this study we sought to examine the contribution of the immune system to bone pain and have created a novel model to study underlying mechanisms.
METHODS: We established a murine prostate cancer bone metastasis pain model in C57BL/6 mice. This was performed by transplanting a HiMyC mouse prostate cancer cell line, into the femur of immunocompetent mice. Behavioral assays were utilized to measure pain development as well as the impact on gait as well as measures of depression and anxiety. Mechanical allodynia was tested using Von Frey fiber testing at 5 day intervals. At 2 months post-injection, behavior changes on Zero maze and digiGait tests were collected. Animal tissues including femurs, dorsal root ganglion and spinal cord were collected at sacrifice and micro-CT and histology/immunohistochemistry were performed.
RESULTS: Mice receiving either 5x104 prostate cancer cells or saline injection into the right femur showed lower threshold for the paw withdrawal response induced by mechanical stimulation. After 3 weeks, the difference on the withdrawal threshold for mechanical allodynia was greater between two groups. At 8 weeks, analysis of the Zero maze and Digigait tests indicated reduced movement capacity and aberrant movement associated emotional activity compared with sham control. Bone samples were scanned with micro-CT and showed typical osteolytic and osteoblastic changes. Furthermore, the trabecular volumes showed ae50% reduction in the prostate cancer group. In examining neural mechanisms, increased CGRP immunoreactivity on the ipsilateral side of tumor-bearing mice at L2-L4 level dorsal root ganglion (DRG) and the corresponding area of the dorsal horn of spinal cord was observed. Differential intracellular trafficking of PGP9.5 was observed which might play an important role in the regulation of nociception input or primary integration in peripheral sensory pathway.
CONCLUSIONS: Our studies describe a novel immunocompetent bone metastasis model that may be utilized to understand prostate cancer metastatic bone pain and the contribution of the immune system to pain development and progression.
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PD65-07 THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON T CELL CHARACTERISTICS IN PROSTATE CANCER PATIENTS
Dixon T. S. Woon*, Melbourne, Australia; Genevieve Whitty, Heidelberg, Australia; Tatenda Nzenza, Melbourne, Australia; Manvendra Saxena, Heidelberg, Australia; Damien Bolton, Melbourne, Australia; Ian Davis, Heidelberg, Australia INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) in prostate cancer (PC) patients can renew lymphopoiesis, reduce tolerance to PC antigens and improve immuno-and chemotherapy responses. ADT can affect the immune system by reconstituting the thymus and influence the T cell profile in prostate tissues. There is limited data on the characteristics of T cells before and after ADT. We aimed to evaluate the proportion of regulatory T cells (Treg), the activation and maturation status of cytotoxic lymphocytes (CTL) in men receiving ADT. We hypothesize that the change in the levels of androgen will affect immune responses, where there will be a down-regulation of immune suppression (lower levels of Treg, higher CD8/Treg ratio), and up-regulation of activation and maturation status of CTLs.
METHODS: Patients who were about to start ADT were recruited. Patients' blood was collected, and peripheral blood mononuclear cells (PBMC) were isolated using Ficoll separation. Using flow cytometry, the proportion of Treg (CD45, CD3, CD4, CD25 and FoxP3þ); percentage of activated CTL(CD45, CD8, CD69þ); CD8/Treg ratio and CD8þ T cell maturation status (based on CD45RA, CD45RO, CCR7 expression) : naive T(TN), effector memory T(TEM), central memory T(TCM), terminal effector T cells (TE) were evaluated before ADT, at 3 months(m) and then at 9-12m post-ADT.
RESULTS: 15 patients with biochemical recurrence, advanced or metastatic PC were recruited. The proportions of Treg before ADT, at 3m and 9-12m after ADT were 2.6%, 2.2%, and 2.1% respectively. Treg decreased by 15% 3m post-ADT (p-value¼0.0098). The CD8þ/Treg ratio for the same interval was 24.6, 41.4, and 42.66 respectively; the ratio increased by 73.4% after 9-12m of ADT (p-value¼0.05). The percentage of activated CD8þ T cells for the same interval was 7.7%, 7.9% and 12% (p-value¼0.19). There was no statistically significant change in the percentages of TCM, TEM, and TE. But the percentage of naive T cells before ADT was 6.73%, after 9-12m of ADT, it decreased significantly to 2.3%(p-value¼0.03).
CONCLUSIONS: This study confirmed that ADT does influence immune responses in PC patients. There was a significant reduction in the percentage of Treg after 3m of ADT, and an increase in the CD8/ Treg ratio after 9-12m of ADT. These suggest there was a reduction in immune suppression during the first year of ADT. There was a significant reduction in the proportion of naive T after 9-12m of ADT. This suggests naive T cells may have developed into other more mature T cell subsets after ADT. Further studies in patients with castrate-resistant PC will be valuable. , and can be proteolyzed by prostate-specific antigen (PSA), resulting in release of the trapped spermatozoa after ejaculation. We have demonstrated that SgI: 1) is overexpressed in prostate cancer cells, which is enhanced by zinc treatment; 2) overexpression in radical prostatectomy specimens correlates with the risk of tumor recurrence; and 3) interacts with androgen receptor (AR) as its co-activator. Meanwhile, several short sequence motifs in AR co-regulators, such as LxxLL (L ¼ leucine; x ¼ any amino acids), have been shown to mediate specific interactions with AR. In the current study, we investigated the role of the LxxLL motif within SgI in its interaction with AR as well as prostate cancer cell growth.
METHODS: We compared the impact of wild-type SgI versus a full-length SgI with mutations in the motif (i.e. LxxAA; A ¼ alanine) on cell viability (via MTT assay), cell migration (via wound-healing assay), AR transcriptional activity (via luciferase reporter gene assay), and interactions with AR (via co-immunoprecipitation). We then assessed the effects of LxxLL/LxxAA peptides on cell growth (via MTT assay/western blot). Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1227
